Dapagliflozin & Metformin Hydrochloride Extended-Release Tablets 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, 10 mg/1000 mg

What is Dapagliflozin & Metformin Hydrochloride Extended-Release Tablets?

Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets combine two medicines with complementary glucose-lowering actions. They are used as part of an appropriate treatment plan for adults with type 2 diabetes mellitus when combination therapy is clinically appropriate. The extended-release formulation is available in four strengths for individualized prescribed treatment.

Uses / Indications

This combination may be used for:

• Improvement of glycemic control in adults with type 2 diabetes mellitus.
• Treatment when both dapagliflozin and metformin are appropriate components of therapy.
• Use alongside diet and physical activity as part of comprehensive type 2 diabetes management.
• Patients requiring combination therapy when treatment with individual components alone does not provide adequate glycemic control, according to the applicable approved indication.

The product is not intended for the treatment of type 1 diabetes unless specifically covered by an approved indication.

Benefits

• Combines two glucose-lowering medicines with complementary mechanisms.
• Dapagliflozin promotes urinary glucose excretion through inhibition of SGLT2.
• Metformin reduces hepatic glucose production and improves insulin sensitivity.
• Extended-release metformin may provide a once-daily formulation depending on the prescribed regimen and approved product information.
• Multiple strengths provide options for individualized treatment plans.

Side Effects

Common Side Effects

Possible side effects may include:

• Increased urination
• Genital fungal infections
• Urinary tract infections
• Nausea
• Diarrhea
• Abdominal discomfort
• Headache
• Dehydration or dizziness

Less Common or Serious Side Effects

Important adverse effects may include:

• Volume depletion and low blood pressure
• Serious urinary or genital infections
• Diabetic ketoacidosis, which can occasionally occur even when blood glucose is not extremely high
• Acute kidney injury or changes in kidney function
• Lactic acidosis associated with metformin, particularly in patients with significant risk factors
• Severe hypoglycemia when used with insulin or insulin secretagogues
• Severe hypersensitivity reactions

Seek urgent medical attention for difficulty breathing, severe weakness, persistent vomiting, abdominal pain, confusion, unusual drowsiness, or other symptoms suggestive of serious adverse reactions.

How Does It Work?

Dapagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney. This reduces glucose reabsorption and increases urinary glucose excretion.

Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, helping increase peripheral glucose utilization.

Together, the two medicines provide complementary mechanisms for lowering blood glucose in appropriate patients with type 2 diabetes.

Dosage Guidelines

The appropriate regimen depends on current glycemic control, kidney function, previous treatment, tolerance, concurrent medicines, and individual clinical circumstances.

• Take the extended-release tablet exactly as prescribed.
• Extended-release tablets should generally be swallowed whole with water.
• Do not crush, chew, or split the extended-release tablet unless specifically permitted by the approved product information.
• Taking the medicine with food may help reduce gastrointestinal effects associated with metformin.
• Kidney function should be assessed before and during treatment as clinically appropriate.
• Adequate fluid intake is important unless fluid restriction has been advised.
• The 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg strengths should be used only according to the prescribed regimen.
• The exact dose and treatment duration should follow the approved product information and the recommendation of a qualified healthcare professional.

When Not to Use

This combination should not be used in patients with:

• Known hypersensitivity to dapagliflozin, metformin, or any component of the formulation.
• Severe renal impairment or conditions where metformin use is contraindicated according to the applicable approved product information.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Conditions associated with significant tissue hypoxia or other major risk factors for metformin-associated lactic acidosis, according to the approved product information.

The complete contraindication profile should be reviewed before treatment.

Drug / Product Interactions

Clinically important interactions may occur with:

• Insulin and insulin secretagogues, which may increase the risk of hypoglycemia.
• Diuretics, which may increase the risk of dehydration or volume depletion.
• Medicines affecting kidney function.
• Certain medicines that may alter metformin exposure or renal elimination.
• Iodinated contrast media in situations where metformin interruption may be required.
• Alcohol, particularly excessive intake, which may increase the risk of metformin-associated lactic acidosis.
• Other glucose-lowering medicines.

A complete medication review is recommended before starting or changing treatment.

Safety Advice

• Monitor blood glucose according to the treatment plan.
• Kidney function should be assessed before initiation and periodically during treatment.
• Maintain adequate hydration, particularly during conditions that may cause fluid loss.
• Seek medical attention for symptoms suggestive of diabetic ketoacidosis, such as nausea, vomiting, abdominal pain, unusual tiredness, difficulty breathing, or confusion.
• Monitor for symptoms of urinary or genital infections.
• Inform the healthcare professional if severe vomiting, diarrhea, fever, prolonged fasting, or significant dehydration occurs.
• Metformin may need to be temporarily withheld in certain acute illnesses, procedures, or contrast-imaging situations according to professional guidance.
• Pregnancy and breastfeeding should be discussed with a qualified healthcare professional before use.
• Children should use this combination only where specifically approved and under appropriate professional supervision.
• If an overdose is suspected, seek immediate medical attention or contact an appropriate poison-control or emergency medical service.

General Instructions

• Take the extended-release tablet exactly according to the prescribed schedule.
• Swallow the tablet whole with water.
• Do not crush, chew, or split the tablet unless the approved product information specifically permits it.
• Take with food when directed to improve gastrointestinal tolerability.
• Do not change the strength or dose without professional guidance.
• Continue recommended dietary and physical-activity measures for diabetes management.
• If a dose is missed, take it when remembered unless it is close to the next scheduled dose. Do not take a double dose.
• Keep the tablets in their original packaging and out of reach of children.

Special Dietary / Lifestyle Tips

• Follow a balanced, diabetes-appropriate diet recommended by a qualified healthcare professional.
• Maintain adequate hydration unless fluid restriction has been advised.
• Maintain regular physical activity appropriate to individual health status.
• Avoid excessive alcohol consumption because it may increase the risk of metabolic complications associated with metformin.
• Monitor blood glucose as recommended.
• During prolonged fasting, severe illness, vomiting, or significant dehydration, seek professional advice regarding continued treatment.

Comparison with Other Treatments

This combination contains an SGLT2 inhibitor and metformin, providing complementary glucose-lowering mechanisms. Other type 2 diabetes treatments include DPP-4 inhibitors, GLP-1 receptor agonists, sulfonylureas, thiazolidinediones, insulin, and other glucose-lowering medicines. Treatment selection depends on glycemic control, kidney function, cardiovascular and renal considerations, adverse-effect risks, concomitant medicines, and individual clinical requirements.

Precautions & Warnings

• Assess kidney function before treatment and periodically thereafter.
• Monitor for dehydration and volume depletion, particularly in older adults and patients taking diuretics.
• Be alert for symptoms of diabetic ketoacidosis, including nausea, vomiting, abdominal pain, malaise, and difficulty breathing.
• Genital and urinary infections may occur and should be treated appropriately.
• Metformin-associated lactic acidosis is rare but serious; risk is increased in certain patients with significant renal impairment, hypoxia, or excessive alcohol use.
• Follow professional instructions regarding temporary treatment interruption during severe illness, prolonged fasting, surgery, or iodinated contrast procedures.
• Inform healthcare professionals about all medicines and supplements being used.
• Pregnancy and breastfeeding require individual professional assessment.

Can I Use It With Other Medicines?

Generally Compatible With

This combination may be prescribed with other glucose-lowering medicines when clinically appropriate. It can be incorporated into individualized diabetes treatment plans under appropriate medical supervision.

Use With Caution / Avoid

Particular caution may be required with:

• Insulin or insulin secretagogues because of increased hypoglycemia risk.
• Diuretics because of potential additional fluid loss.
• Medicines that can impair kidney function.
• Iodinated contrast media, where metformin-related precautions may apply.
• Excessive alcohol consumption.
• Other medicines that may affect blood glucose or fluid balance.

A healthcare professional should review the complete medication list before combined use.

Storage

Store according to the storage conditions stated on the approved product label and package insert.

• Keep the tablets in the original packaging.
• Protect from excessive heat, moisture, and light where applicable.
• Keep the pack properly closed when not in use.
• Keep out of reach of children.
• Do not use the product after its expiry date.

Frequently Asked Questions

1. What is Dapagliflozin & Metformin Hydrochloride Extended-Release Tablets used for?

This combination is used as part of the treatment of type 2 diabetes mellitus in adults when both dapagliflozin and metformin are appropriate.

2. What strengths are available?

The product is available in four strengths: 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg of dapagliflozin/metformin hydrochloride, respectively.

3. How does the combination work?

Dapagliflozin increases urinary glucose excretion by inhibiting SGLT2 in the kidney, while metformin reduces hepatic glucose production and improves insulin sensitivity.

4. Should the extended-release tablet be crushed or chewed?

Extended-release tablets should generally be swallowed whole with water. They should not be crushed, chewed, or split unless specifically permitted by the approved product information.

5. Can this medicine cause low blood sugar?

Dapagliflozin and metformin alone generally have a low risk of hypoglycemia. However, the risk can increase when the combination is used with insulin or insulin secretagogues.

6. Why is kidney function important with this medicine?

Both components require consideration of kidney function. Renal impairment can affect treatment suitability and increase the risks associated with metformin and dapagliflozin.

7. What are important warning symptoms during treatment?

Severe dehydration, persistent vomiting, abdominal pain, unusual weakness, difficulty breathing, confusion, or symptoms of serious urinary or genital infection require prompt medical assessment.

8. What should I do if I miss a dose?

Take the missed dose when remembered unless it is close to the next scheduled dose. Do not take an extra or double dose to compensate.